<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: Biological agents are therapies designed to target a specific molecular component of the immune system, and are currently licensed for use in autoimmune rheumatic, digestive, dermatological and <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, their use has been linked with the paradoxical development of autoimmune processes </plain></SENT>
<SENT sid="2" pm="."><plain>RECENT FINDINGS: More than 1500 cases of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> induced by biologics have been reported, including a wide variety of both systemic (<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>, <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e>, <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and <z:hpo ids='HP_0009071'>inflammatory myopathies</z:hpo>) and organ-specific (<z:hpo ids='HP_0006530'>interstitial lung disease</z:hpo>, <z:hpo ids='HP_0000554'>uveitis</z:hpo>, <z:hpo ids='HP_0100653'>optic neuritis</z:hpo>, <z:hpo ids='HP_0009830'>peripheral neuropathies</z:hpo>, multiple <z:mp ids='MP_0000612'>sclerosis</z:mp>, <z:hpo ids='HP_0003765'>psoriasis</z:hpo>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> and autoimmune <z:hpo ids='HP_0012115'>hepatitis</z:hpo>) autoimmune processes </plain></SENT>
<SENT sid="3" pm="."><plain>Although these processes are overwhelmingly associated with anti-TNF agents, recent cases have been associated with therapies directed against other cytokines, B or T-cells, illustrating that even though targeting a particular immune molecule may be associated with an excellent clinical response in most patients, an unexpected <z:mp ids='MP_0001844'>autoimmune response</z:mp> may arise in some cases </plain></SENT>
<SENT sid="4" pm="."><plain>SUMMARY: As the use of biological therapies expands, the number and diversity of induced <z:hpo ids='HP_0002960'>autoimmune disorders</z:hpo> should be expected to increase </plain></SENT>
<SENT sid="5" pm="."><plain>Paradoxically, for many of these drug-related processes, current treatment indications include the very biological agent producing the adverse event </plain></SENT>
</text></document>